Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC with Cisplatin/5-FU + Lipiodol in Advanced HCC
NCT06632717Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, fluorouracil and ethiodized oil in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Primary endpoint: Objective Response Rate (RECIST 1.1) up to 60 months. Started Sep 2024; status: recruiting.
02
Drugs
cisplatinfluorouracilethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06632717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632717.